AccuRna Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
23
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$16M
AccuRna General Information
Description
Developer of drug delivery systems designed for nucleic acid therapeutics. The company offers proprietary nanotechnology platforms, including unit polyion complexes and polyplex micelles that stabilize and transport short-chain and long-chain nucleic acids, enabling pharmaceutical companies and research institutions to deliver innovative medicines for refractory diseases and cancer.
Contact Information
Website
www.accurna.com(Operating Subsidiary)
Corporate Office
- Sanyu Building 201, 3-42-1
- Hongo
- Bunkyo-ku, Tokyo
- Japan
Corporate Office
- Sanyu Building 201, 3-42-1
- Hongo
- Bunkyo-ku, Tokyo
- Japan
AccuRna Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 01-Sep-2020 | $16M | Completed | Clinical Trials - General | ||
| 3. Early Stage VC | 23-Dec-2019 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC | 17-Jan-2018 | $4.65M | $5.95M | Completed | Startup | |
| 1. Seed Round | 16-Mar-2016 | $1.3M | $1.3M | Completed | Startup |
AccuRna Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class B2 preferred | ||||||||
| Class B preferred | ||||||||
| Class A preferred | 4,900 | $274.88 | $274.88 | 1x | $274.88 | 18.1% |
AccuRna Patents
AccuRna Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3135763-A1 | Method for improving protein expression, and composition for protein expression | Inactive | 24-Apr-2014 | ||
| EP-3135763-A4 | Method for improving protein expression, and composition for protein expression | Inactive | 24-Apr-2014 | ||
| US-20170183389-A1 | Method for improving protein expression, and composition for protein expression | Inactive | 24-Apr-2014 | C07K14/65 |
AccuRna Signals
AccuRna Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Fast Track Initiative | Venture Capital | Minority | ||
| SMBC Venture Capital | Corporate Venture Capital | Minority | ||
| UTokyo Innovation Platform | Accelerator/Incubator | Minority |
AccuRna FAQs
-
When was AccuRna founded?
AccuRna was founded in 2015.
-
Where is AccuRna headquartered?
AccuRna is headquartered in Bunkyo-ku, Japan.
-
What is the size of AccuRna?
AccuRna has 23 total employees.
-
What industry is AccuRna in?
AccuRna’s primary industry is Drug Delivery.
-
Is AccuRna a private or public company?
AccuRna is a Private company.
-
What is the current valuation of AccuRna?
The current valuation of AccuRna is .
-
What is AccuRna’s current revenue?
The current revenue for AccuRna is .
-
How much funding has AccuRna raised over time?
AccuRna has raised $8.24M.
-
Who are AccuRna’s investors?
Fast Track Initiative, SMBC Venture Capital, and UTokyo Innovation Platform have invested in AccuRna.
-
When was AccuRna acquired?
AccuRna was acquired on 01-Sep-2020.
-
Who acquired AccuRna?
AccuRna was acquired by Nano Holdings.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process